Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: Retrospective analysis of 21 cases

American Journal of Hematology

Volumn 79, Issue 4, 2005, Pages 329-331

  Chen, Yeu Chin ^a,b   Chou, Jung Mao ^a,b   Letendre, Louis ^a   Li, Chin Yang ^a  

^a MAYO CLINIC   (United States)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Acute myeloid leukemia; Chronic myelomonocytic leukemia; Monocytic nodules; Myelodysplastic syndromes; Myeloproliferative diseases

Indexed keywords

CALCITRIOL; CORTICOSTEROID; DANAZOL; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; FEMALE; HUMAN; IRON CHELATION; MALE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PANCYTOPENIA; PRIORITY JOURNAL; REFRACTORY ANEMIA; RELAPSE; REMISSION; RETROSPECTIVE STUDY; REVIEW; SPLENECTOMY; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; BONE MARROW CELLS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 23244467946     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20410     Document Type: Review

References (10)

1. Chen YC, Chou JM, Ketterling RP, Letendre L, Li CY. Histologic and immunohistocliemical study of bone marrow monocytic nodules in 21 cases with myelodysplasia. Am J Clin Pathol 2003; 120:874-881.
2. Mongkonsritragoon W, Letendre L, Qian J, Li CY. Nodular lesions of monocytic component in myelodysplastic syndrome. Am J Clin Pathol 1998;110:154-162.
3. Brunning RD, Bennett JM, Flandrin G, et al. Myelodysplastic syndromes. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: pathology and genetics of hematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. p 61-73.
4. Vardiman JW, Pierre R, Bain B, et al. Myelodysplastic/myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumours: pathology and genetics of hematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001. p 45-59.
5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
6. Sanz GF, Sanz MA. Prognostic factors in myelodysplastic syndromes. Leuk Res 1992;16:77-86.
7. Nösslinger T, Reisner R, Gruner H, et al. Dysplastic versus proliferative CMML: a retrospective analysis of 91 patients from a single institution. Leuk Res 2001;25:741-747.
8. Gambier N, Baruchel A, Schlageter MH, et al. Chronic myelomonocytic leukemia: from biology to therapy. Hematol Cell Ther 1997; 39:41-48.
9. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 2000;257:231-237.
10. Walker JV, Nitiss JL. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest 2002;20:570-589.